Newswise — April 1, 2020 – The initial experience of extracorporeal membrane oxygenation (ECMO) management for coronavirus 2019 (COVID-19) patients in Shanghai, China provides guidance for management of critically ill COVID-19 patients worldwide, reports a study in the ASAIO Journal. The journal is published in the Lippincott portfolio by Wolters Kluwer.

For the most critically ill COVID-19 patients, standard ventilator care may not provide adequate support while allowing the lungs to heal and recover. Xin Li, MD and colleagues from University of Louisville, Louisville, KY and Zhongshan Hospital, Shanghai, China report on COVID-19 patients in China managed with ECMO and their outcomes, to guide health practitioners in treating this challenging patient population during the worldwide pandemic.

Because there is little worldwide experience using ECMO to support COVID-19 patients, Zhongshan Hospital established a dedicated ECMO team consisting of a physician perfusionist, a critical care physician, and a pulmonologist to be available at all times to oversee ECMO management of COVID-19 patients. The team was also responsible for communicating with the newly established Shanghai COVID-19 ECMO Expert Team, a group of 12 ECMO units from Shanghai's major hospitals. Together they developed the “Shanghai ECMO Support for COVID-19 Guideline” to ensure consistency and standardization across all hospital centers.

The report details the management and outcomes of eight COVID-19 patients treated with ECMO. The article is freely available in a special online COVID-19 section of ASAIO Journal.

Click here to read “Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019 in Shanghai, China.”

DOI: 10.1097/MAT.0000000000001172


About ASAIO Journal

ASAIO Journal, the official publication of the American Society for Artificial Internal Organs, is in the forefront of artificial organ research and development. On the cutting edge of innovative technology, it features peer-reviewed articles of the highest quality that describe research, development, the most recent advances in the design of artificial organ devices and findings from initial testing. Published in eight issues annually, the ASAIO Journal features state-of-the-art investigations, laboratory and clinical trials, and discussions and opinions from experts around the world.

For more information, visit, follow the journal on Twitter, Facebook, LinkedIn, and YouTube.

About Wolters Kluwer

Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.

Wolters Kluwer reported 2018 annual revenues of €4.3 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 18,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students with advanced clinical decision support, learning and research and clinical intelligence. For more information about our solutions, visit and follow us on LinkedIn and Twitter @WKHealth.

For more information, visit, follow us on TwitterFacebookLinkedIn, and YouTube.

Journal Link: ASAIO Journal